What is Solasta Bio?
Solasta Bio is a pioneering force in the agricultural biotechnology landscape, specializing in the discovery and development of selective, peptide-based insect control agents. By leveraging advanced molecular biology, the company creates compounds that disrupt specific biological functions in target pest species while ensuring minimal impact on beneficial insects and vertebrates. This approach addresses the critical global demand for greener, low-residue crop protection methods that align with modern regulatory standards and environmental stewardship goals. By bridging the gap between laboratory innovation and field-ready application, Solasta Bio is redefining the standards for sustainable pest management in global agriculture.
How much funding has Solasta Bio raised?
Solasta Bio has raised a total of $19M across 2 funding rounds:
Other Financing Round
$5M
Series A
$14M
Other Financing Round (2023): $5M with participation from Scottish Enterprise, Rubio Impact Ventures, SIS Ventures, Cavallo Ventures, and Yield Lab Europe
Series A (2024): $14M led by Forbion
Key Investors in Solasta Bio
Forbion
A global life sciences venture capital firm with a strong track record in building biotech companies, focusing on innovative therapeutics and sustainable solutions through its BioEconomy fund strategy.
Cavallo Ventures
The venture capital arm of Wilbur Ellis, providing deep agricultural market expertise and capital to support innovative technologies that maximize crop production efficiency.
Scottish Enterprise
A national economic development agency of the Scottish Government that supports high-growth potential enterprises through strategic investment and business development resources.
What's next for Solasta Bio?
With the recent infusion of capital, Solasta Bio is poised to scale its research and development operations, focusing on the optimization of its peptide-based pipeline for broader market adoption. The company is expected to prioritize regulatory milestones and strategic partnerships that facilitate the integration of its technology into existing agricultural supply chains. As the firm moves deeper into its Series A lifecycle, the focus will likely shift toward field trials and the establishment of manufacturing capabilities, ensuring that its sustainable solutions can meet the rigorous demands of large-scale commercial farming operations while maintaining its commitment to ecological safety.
See full Solasta Bio company page
